93 related articles for article (PubMed ID: 8648606)
1. Use of a dipeptide chemical library in the development of non-peptide tachykinin NK3 receptor selective antagonists.
Boden P; Eden JM; Hodgson J; Horwell DC; Hughes J; McKnight AT; Lewthwaite RA; Pritchard MC; Raphy J; Meecham K; Ratcliffe GS; Suman-Chauhan N; Woodruff GN
J Med Chem; 1996 Apr; 39(8):1664-75. PubMed ID: 8648606
[TBL] [Abstract][Full Text] [Related]
2. Activation of the cloned human NK3 receptor in Chinese Hamster Ovary cells characterized by the cellular acidification response using the Cytosensor microphysiometer.
Jordan RE; Smart D; Grimson P; Suman-Chauhan N; McKnight AT
Br J Pharmacol; 1998 Oct; 125(4):761-6. PubMed ID: 9831912
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).
Giardina GA; Raveglia LF; Grugni M; Sarau HM; Farina C; Medhurst AD; Graziani D; Schmidt DB; Rigolio R; Luttmann M; Cavagnera S; Foley JJ; Vecchietti V; Hay DW
J Med Chem; 1999 Mar; 42(6):1053-65. PubMed ID: 10090788
[TBL] [Abstract][Full Text] [Related]
4. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist.
Catalioto RM; Criscuoli M; Cucchi P; Giachetti A; Gianotti D; Giuliani S; Lecci A; Lippi A; Patacchini R; Quartara L; Renzetti AR; Tramontana M; Arcamone F; Maggi CA
Br J Pharmacol; 1998 Jan; 123(1):81-91. PubMed ID: 9484857
[TBL] [Abstract][Full Text] [Related]
5. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
[TBL] [Abstract][Full Text] [Related]
6. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
Cialdai C; Tramontana M; Patacchini R; Lecci A; Catalani C; Catalioto RM; Meini S; Valenti C; Altamura M; Giuliani S; Maggi CA
Eur J Pharmacol; 2006 Nov; 549(1-3):140-8. PubMed ID: 16979621
[TBL] [Abstract][Full Text] [Related]
7. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.
Sarau HM; Griswold DE; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Webb EF; Martin LD; Legos JJ; Whitmore RG; Barone FC; Medhurst AD; Luttmann MA; Giardina GA; Hay DW
J Pharmacol Exp Ther; 2000 Oct; 295(1):373-81. PubMed ID: 10992004
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity.
Devadas B; Freeman SK; Zupec ME; Lu HF; Nagarajan SR; Kishore NS; Lodge JK; Kuneman DW; McWherter CA; Vinjamoori DV; Getman DP; Gordon JI; Sikorski JA
J Med Chem; 1997 Aug; 40(16):2609-25. PubMed ID: 9258368
[TBL] [Abstract][Full Text] [Related]
10. Characterization of receptors mediating contraction induced by tachykinins in the guinea-pig isolated common bile duct.
Patacchini R; Barthó L; Maggi CA
Br J Pharmacol; 1997 Dec; 122(8):1633-8. PubMed ID: 9422808
[TBL] [Abstract][Full Text] [Related]
11. Molecular and pharmacological characterization of a functional tachykinin NK3 receptor cloned from the rabbit iris sphincter muscle.
Medhurst AD; Hirst WD; Jerman JC; Meakin J; Roberts JC; Testa T; Smart D
Br J Pharmacol; 1999 Oct; 128(3):627-36. PubMed ID: 10516642
[TBL] [Abstract][Full Text] [Related]
12. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia.
Dawson LA; Cato KJ; Scott C; Watson JM; Wood MD; Foxton R; de la Flor R; Jones GA; Kew JN; Cluderay JE; Southam E; Murkitt GS; Gartlon J; Pemberton DJ; Jones DN; Davies CH; Hagan J
Neuropsychopharmacology; 2008 Jun; 33(7):1642-52. PubMed ID: 17728699
[TBL] [Abstract][Full Text] [Related]
14. Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor.
Geldenhuys WJ; Kuzenko SR; Simmons MA
J Med Chem; 2010 Nov; 53(22):8080-8. PubMed ID: 21047106
[TBL] [Abstract][Full Text] [Related]
15. Systematic optimization of a lead-structure identities for a selective short peptide agonist for the human orphan receptor BRS-3.
Weber D; Berger C; Heinrich T; Eickelmann P; Antel J; Kessler H
J Pept Sci; 2002 Aug; 8(8):461-75. PubMed ID: 12212809
[TBL] [Abstract][Full Text] [Related]
16. Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3.
Leffler A; Ahlstedt I; Engberg S; Svensson A; Billger M; Oberg L; Bjursell MK; Lindström E; von Mentzer B
Biochem Pharmacol; 2009 May; 77(9):1522-30. PubMed ID: 19426690
[TBL] [Abstract][Full Text] [Related]
17. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.
Emonds-Alt X; Proietto V; Steinberg R; Oury-Donat F; Vigé X; Vilain P; Naline E; Daoui S; Advenier C; Le Fur G; Maffrand JP; Soubrié P; Pascal M
J Pharmacol Exp Ther; 2002 Dec; 303(3):1171-9. PubMed ID: 12438541
[TBL] [Abstract][Full Text] [Related]
18. Characterization of tachykinin receptors in the uterus of the oestrogen-primed rat.
Magraner J; Pinto FM; Anselmi E; Hernandez M; Perez-Afonso R; Martín JD; Advenier C; Candenas ML
Br J Pharmacol; 1998 Jan; 123(2):259-68. PubMed ID: 9489614
[TBL] [Abstract][Full Text] [Related]
19. Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin3 receptor.
Chung FZ; Wu LH; Tian Y; Vartanian MA; Lee H; Bikker J; Humblet C; Pritchard MC; Raphy J; Suman-Chauhan N
Mol Pharmacol; 1995 Oct; 48(4):711-6. PubMed ID: 7476898
[TBL] [Abstract][Full Text] [Related]
20. Characterization of tachykinin mediated increases in [Ca2+]i in Chinese hamster ovary cells expressing human tachykinin NK3 receptors.
Pinnock RD; Suman-Chauhan N; Chung FZ; Webdale L; Madden Z; Hill DR; Woodruff GN
Eur J Pharmacol; 1994 Sep; 269(1):73-8. PubMed ID: 7530208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
